<SEC-DOCUMENT>0001628280-24-010878.txt : 20240313
<SEC-HEADER>0001628280-24-010878.hdr.sgml : 20240313
<ACCEPTANCE-DATETIME>20240313153817
ACCESSION NUMBER:		0001628280-24-010878
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240312
FILED AS OF DATE:		20240313
DATE AS OF CHANGE:		20240313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CYBIN INC.
		CENTRAL INDEX KEY:			0001833141
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40673
		FILM NUMBER:		24745817

	BUSINESS ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
		BUSINESS PHONE:		(908) 764-8385

	MAIL ADDRESS:	
		STREET 1:		100 KING STREET WEST
		STREET 2:		SUITE 5600
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5X 1C9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cybininc-form6xk03x13x2024.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="icd69db6d45a14329a1d1bfe23e480224_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="-sec-extract:summary;margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Washington, D.C. 20549</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Form 6-K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>UNDER THE SECURITIES EXCHANGE ACT OF 1934</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the month of March, 2024.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Commission File Number&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">001-40673</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Exact Name of Registrant as Specified in Charter)<br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">100 King Street West, Suite 5600, Toronto, Ontario, M5X 1C9 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Address of principal executive offices) </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Form 20-F  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:115%">&#9633;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  Form 40-F &#8864;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURE</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.<br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:5.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CYBIN INC.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Registrant)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March 13, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#47;s&#47; Doug Drysdale&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Doug Drysdale</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline">EXHIBIT INDEX</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.820%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a href="a03-12x2024cybincurtainrai.htm" style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">News Release dated March 12, 2024</a></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a03-12x2024cybincurtainrai.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if2591776ffdc41d394effe20c40dea5c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:147px;margin-bottom:5pt;vertical-align:text-bottom;width:253px"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:133%">Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- Program update includes 4-month durability data from Phase 2 trial of CYB003 in Major Depressive Disorder (&#8220;MDD&#8221;) -</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:133%">- Company speakers include Doug Drysdale, Chief Executive Officer and Amir Inamdar, MBBS, DNB (Psych), MFPM, Chief Medical Officer -</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%"><br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">TORONTO, CANADA </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8211; March 12, 2024 &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Cybin Inc.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> (NYSE American&#58;CYBN) (Cboe CA&#58;CYBN) (&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Cybin</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Company</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">&#8221;), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced that it will host a conference call and webcast at 8&#58;30 a.m. ET on Wednesday, March 13, 2024. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The Company will provide a program update on CYB003,</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> its proprietary deuterated psilocybin analog in development for the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">adjunctive</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> treatment of MDD,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> including 4-month durability results from the Company&#8217;s Phase 2 trial.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Conference Call and Webcast Details&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Wednesday, March 13, 2024</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Time&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8&#58;30 a.m. ET.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Dial-in&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;800-267-6316 (U.S. Toll-Free) or 203-518-9783 (International)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Conference ID&#58;&#160;&#160;&#160;&#160;CYBN0313</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Webcast&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Register for the webcast </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">here</font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">The archived webcast will also be available on the Company&#8217;s investor relations website on the </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">Events &#38; Presentations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> page.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">About Cybin</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin&#8217;s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The Company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:133%">Investor &#38; Media Contact&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Gabriel Fahel</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Legal Officer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Cybin Inc.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%">1-866-292-4601</font></div><div><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">irteam&#64;cybin.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> &#8211; or &#8211; </font><font style="color:#0563c1;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:133%;text-decoration:underline">media&#64;cybin.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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MX+XF2J$\^4 <A:@"!<P\=C&QF_R\B3JQH<$#::\P%2*+%\;1B[^9]@]3(>I
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MA6GO[&]Z1Y@.$KJ);!JF[M"B2"P/WJ<HY!^,F2^8?AFF"R&XDMBHK/,!4%O
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M)$MA:Y_!$OHV>1>7Y0%QS(&5'AFJ74'Q>%_!$JC)]"KR]SJ.X^B5.[YE#Y9
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MG":4; I=$W10\2JE^(QI3%G%0HR.V@+F3>(HVD%3V#>$:3:>3C>U@REST^_
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M3/N&J1!"](,"INB2Y\:Q#7N;#@Q3(83H#P5,T27GF=JTX**SR9%A*H00_:*
M*;KF':9'F-9/7LWF#R9Z9KYW\DH((2I  5/TP;&FFY@.,9UF(B'H;!/>L$>8
A;FKZE$D((2KA<I?[_[P*ZV0DJ0MG     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
